KOERS GALAPAGOS 2015

16.480 Posts, Pagina: « 1 2 3 4 5 6 ... 249 250 251 252 253 254 255 256 257 258 259 ... 820 821 822 823 824 » | Laatste
B...K
0
Plussen op Wall Street
Gepubliceerd op 1 mei 2015 om 19:30 | Views: 1.171

Verder waren aandelen van biotechbedrijven in trek in New York, na sterke kwartaalcijfers van Gilead (plus 5,4 procent). Branchegenoten Celgene en Biogen wisten mee te liften en stegen respectievelijk 1,9 procent en 3,3 procent.
SJURVM
0
Indeed, what are a few euros here or there when we are offered that kind of money.
Thr art of mental arithmetic is being lost these days. I can only applaud your efforts your use of pen and paper. :)

Zouph
0
how many days before the Nasday registration do they announce the date? Are there rules about that? Onno says 2-3 weeks but i want to know it exactly because its important for my may calls which will expire the 22th ;)
NielsjeB
0
quote:

SJURVM schreef op 1 mei 2015 20:52:


latest changes for NAsdaq registration

www.sec.gov/cgi-bin/browse-edgar?acti...

Fascinating stuff really, but a lot of material. For example, anything from the AbbVie agreement we did not yet know?

www.sec.gov/Archives/edgar/data/14218...
NielsjeB
0
quote:

Zouph schreef op 1 mei 2015 20:59:


how many days before the Nasday registration do they announce the date? Are there rules about that? Onno says 2-3 weeks but i want to know it exactly because its important for my may calls which will expire the 22th ;)

I believe it's actually May 15th. Expiration is on the third Friday of the month. Today is a Friday.
SJURVM
0
quote:

NielsjeB schreef op 1 mei 2015 21:11:


[...]
Fascinating stuff really, but a lot of material. For example, anything from the AbbVie agreement we did not yet know?

www.sec.gov/Archives/edgar/data/14218...


No, it confirms the $200m + $1bn + the tiered royalties from low teens to low twenties payments.

They are indeed pretty long those forms.
NielsjeB
0
quote:

SJURVM schreef op 1 mei 2015 21:16:


[...]

No, it confirms the $200m + $1bn + the tiered royalties from low teens to low twenties payments.

They are indeed pretty long those forms.

Yep, most if not all of the interesting bits are left out of course.
B...K
0
AMSTERDAM (Dow Jones)--Galapagos nv (GLPG.AE) heeft warrants gecreeerd en aangeboden aan werknemers en bestuurders, meldt het biotechbedrijf vrijdag.

In totaal zijn er 625.740 warrants gemaakt. Deze zijn hoofdzakelijk aan werknemers aangeboden en ook aan bestuurders.

De warrants hebben een uitoefentermijn van 8 jaar vanaf de datum van het aanbod en een uitoefenprijs van EUR28,75. Ze zijn niet overdraagbaar en krijgen geen notering.

Ieder warrant geeft het recht om in te schrijven op 1 nieuw aandeel Galapagos.


Door Levien de Feijter; Dow Jones Nieuwsdienst: +31-20-5715200; levien.defeijter@wsj.com


(END) Dow Jones Newswires

May 01, 2015 12:08 ET (16:08 GMT)

*Binck is niet aansprakelijk voor informatie verschaft door derden
[verwijderd]
0
Ik zit eraan te denken om maandag bij te kopen om tegelijk calls te schrijven. Welke calls twijfel ik nog aan, mei en dan ergens eind 30 omdat ik niet veel in de koers verwacht de komende weken of dec of jan 50 ofzo. Huidige positie hou ik en mocht de koers exploderen dan pak ik de stijging tot 50 + premie. Keuzes keuzes.....maar heb nog een weekend om erover na te denken
SJURVM
0
the underwriters bit is left blank to as toamount each will take but it is fully underwritten. They have agreed that only 5% of the share offering will go their discretionary accounts
Morgan Stanley & Co. LLC
Credit Suisse Securities (USA) LLC
Cowen and Company, LLC
Nomura Securities International, Inc.
Bryan, Garnier & Co.
SJURVM
0
As of April 30, 2015, €28,149,101.01 of the authorized capital was used, so that an amount of €114,441,669.43 still remained available under the authorized capital, assuming all 625,740 new warrants under Warrant Plan 2015 are accepted by the plan’s beneficiaries.

As of the date of this prospectus and assuming full acceptance of the new warrants offered under Warrant Plan 2015, our board of directors may decide to issue up to 21,153,728 ordinary shares pursuant to this authorization, without taking into account however the shares that we will issue in this global offering or subsequent issuances under our warrant programs or otherwise.
NielsjeB
1
Het "AbbVie-neemtlicentiemaardoetverderniks"-risico staat netjes genoemd in het prospectus voor de NASDAQ-notering:

"For example, if AbbVie in-licenses filgotinib following the availability of Phase 2b results in RA, AbbVie will have control of any commercialization in the event filgotinib is approved with limited exceptions. It is possible that a partner may not devote sufficient resources to the development or commercialization of our product candidate or may otherwise fail in development or commercialization efforts, in which event the development and commercialization of such product candidate could be delayed or terminated and our business could be substantially harmed."
SJURVM
0
Yes that is part of the "risk factors" one has to put in a prospectus.

I think this has been discussed at length on this forum as to why Abbvie would do such a thing. Unless their own was as good as filgotinib.
On the balance of probabilities Abbvie is in more need to replace Humira with another blockbuster than not do the right commercial thing.

Financially a take-over is cheaper (and they would get the other programs too).

But yes if the so wished for whatever reason to could leave the grapes to dry out on the vine as it were.
Zouph
0
quote:

NielsjeB schreef op 1 mei 2015 21:12:


[...]
I believe it's actually May 15th. Expiration is on the third Friday of the month. Today is a Friday.


you are right, thanks for pointing this out
NielsjeB
0
quote:

SJURVM schreef op 1 mei 2015 21:48:


Yes that is part of the "risk factors" one has to put in a prospectus.

I think this has been discussed at length on this forum as to why Abbvie would do such a thing. Unless their own was as good as filgotinib.
On the balance of probabilities Abbvie is in more need to replace Humira with another blockbuster than not do the right commercial thing.

Financially a take-over is cheaper (and they would get the other programs too).

But yes if the so wished for whatever reason to could leave the grapes to dry out on the vine as it were.

Still good to see these risk factors now and then ;)
I think the only real risk is that their own study gives the same or better results.
SJURVM
0
Galapagos NV (GLPYY) -Other OTC
Watchlist
42.58 Up 0.13(0.31%)

At least the share price went up today in the US :)

16.480 Posts, Pagina: « 1 2 3 4 5 6 ... 249 250 251 252 253 254 255 256 257 258 259 ... 820 821 822 823 824 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 30 jul 2021 17:35
Koers 51,210
Verschil -0,130 (-0,25%)
Hoog 51,570
Laag 50,440
Volume 226.161
Volume gemiddeld 489.399
Volume gisteren 230.730